Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Washington
Seagen Inc.
National Institutes of Health Clinical Center (CC)
SystImmune Inc.
Mersana Therapeutics
M.D. Anderson Cancer Center
Numab Therapeutics AG
Lyell Immunopharma, Inc.
Mayo Clinic
ADC Therapeutics S.A.
City of Hope Medical Center
Celldex Therapeutics
Gilead Sciences
Xencor, Inc.
Xencor, Inc.
University of California, San Francisco
AstraZeneca
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
University of Chicago
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Santa Maria Biotherapeutics
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
NYU Langone Health